Trevi Therapeutics, Inc.
TRVI
$13.35
$0.050.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.06% | -18.97% | 9.42% | 13.80% | -7.21% |
| Total Depreciation and Amortization | 0.00% | 2.70% | -2.63% | 5.56% | -5.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.22% | 20.11% | 13.08% | 64.59% | -45.02% |
| Change in Net Operating Assets | -116.08% | 125.64% | -506.24% | -68.00% | 15.62% |
| Cash from Operations | -7.71% | 25.05% | -41.12% | 0.06% | -10.05% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,851.19% | 73.77% | 58.30% | -411.27% | 174.21% |
| Cash from Investing | -1,851.65% | 73.77% | 58.32% | -411.36% | 176.99% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 64.52% | 3.13% | -3.23% |
| Issuance of Common Stock | -98.99% | 1,139.24% | -82.64% | 927.90% | -1.73% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 237.50% | -65.77% | -- | -- | -- |
| Cash from Financing | -98.52% | 1,168.18% | -83.09% | 933.89% | -1.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -161.62% | 763.48% | -181.59% | 484.17% | 464.27% |